Shares of Envista Holdings Corporation (NYSE:NVST - Get Free Report) have been assigned an average recommendation of "Hold" from the sixteen analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $20.9231.
Several research firms have commented on NVST. Morgan Stanley boosted their target price on shares of Envista from $16.00 to $17.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Wells Fargo & Company upped their price objective on shares of Envista from $17.00 to $19.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Mizuho increased their target price on shares of Envista from $15.00 to $18.00 and gave the stock an "underperform" rating in a research report on Friday, August 1st. Wall Street Zen cut Envista from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 30th. Finally, Stifel Nicolaus increased their price objective on Envista from $24.00 to $25.00 and gave the company a "buy" rating in a report on Friday, August 1st.
Check Out Our Latest Research Report on Envista
Envista Price Performance
NVST opened at $20.37 on Wednesday. The stock has a fifty day moving average price of $20.72 and a 200 day moving average price of $18.79. The company has a current ratio of 2.44, a quick ratio of 2.08 and a debt-to-equity ratio of 0.46. Envista has a 1 year low of $14.22 and a 1 year high of $23.00. The stock has a market cap of $3.39 billion, a price-to-earnings ratio of 63.66, a PEG ratio of 1.08 and a beta of 0.99.
Envista (NYSE:NVST - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.24 by $0.02. The company had revenue of $682.10 million during the quarter, compared to the consensus estimate of $638.21 million. Envista had a return on equity of 4.84% and a net margin of 2.11%.The business's quarterly revenue was up 7.7% on a year-over-year basis. During the same period last year, the business earned $0.11 EPS. Envista has set its FY 2025 guidance at 1.050-1.15 EPS. Analysts forecast that Envista will post 1 EPS for the current fiscal year.
Institutional Trading of Envista
Several large investors have recently modified their holdings of NVST. UMB Bank n.a. raised its holdings in Envista by 214.4% in the 1st quarter. UMB Bank n.a. now owns 2,094 shares of the company's stock worth $36,000 after acquiring an additional 1,428 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Envista by 73.1% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company's stock valued at $44,000 after purchasing an additional 949 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Envista by 378.0% in the second quarter. EverSource Wealth Advisors LLC now owns 2,414 shares of the company's stock worth $47,000 after purchasing an additional 1,909 shares during the period. Parallel Advisors LLC lifted its position in shares of Envista by 100.1% during the 2nd quarter. Parallel Advisors LLC now owns 2,792 shares of the company's stock worth $55,000 after purchasing an additional 1,397 shares during the last quarter. Finally, Palouse Capital Management Inc. boosted its stake in Envista by 14.4% during the 1st quarter. Palouse Capital Management Inc. now owns 9,444 shares of the company's stock valued at $163,000 after purchasing an additional 1,186 shares during the period.
Envista Company Profile
(
Get Free Report)
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Envista, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.
While Envista currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.